drugset / Trial / NCT01020786

A Study in Non-squamous Non Small Cell Lung Cancer in Asian Patients

NCT01020786

Phase 4 Completed 109 enrolled Eli Lilly and Company
NaSingle-groupOpen-labelTreatment

Summary

To investigate efficacy and safety of the combination with pemetrexed plus carboplatin, followed by pemetrexed in patients with advanced nonsquamous Non Small Cell Lung Cancer (NSCLC) who receive at least one dose of the induction therapy.

Timeline

Start
2009-11
Primary completion
2011-03
Completion
2012-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Carboplatin Small molecule 6 unknown Intravenous
Subject Pemetrexed Small molecule 500 mg/m2 Intravenous